A Phase I Trial of KRN5500 (NSC 650426) Given as a 72 Hour Continuous IV Infusion Every 21 Days in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Jan 2013
At a glance
- Drugs KRN 5500 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 10 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Sep 2005 New trial record.